Clinical

Videos

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

Neal D. Shore, MD, on the Importance of Multidisciplinary Care in Advanced Prostate Cancer

Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.

Petros Grivas, MD, PhD, on Updates in Genitourinary Oncology From ASCO 2021

Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.

Petros Grivas, MD, PhD, on the Impact of First-Line Maintenance Avelumab in Advanced Urothelial Carcinoma

Articles

Pembrolizumab plus gemcitabine and concurrent hypofractionated radiotherapy to treat patients with MIBC demonstrated safety and efficacy.

Trimodal Pembrolizumab-Based Combo Shows Safety and Efficacy Treating MIBC

Based on results of the recently reported phase 3 CheckMate 274 trial, the FDA has granted priority review designation to nivolumab for the adjuvant treatment of high-risk muscle-invasive bladder cancer.

Nivolumab Granted Priority Review as Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma

Accelerated approval for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for certain chemotherapy regimens was maintained by an FDA committee vote. 

ODAC Decision Means Atezolizumab Will Maintain It’s Indication for Frontline Urothelial Carcinoma 

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

New Potential Frontline Standards for RCC Are Spotlighted at Genitourinary Cancers Symposium

Based on results from the EV-301 and EV-201 trials, 2 separate applications for enfortumab vedotin as therapy for certain patients with previously treated metastatic urothelial carcinoma were accepted by the FDA and granted priority review. 

Priority Review Granted to Two Applications for Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Based on results of the phase 2 TROPHY-U-01 trial, the FDA has given accelerated approval to sacituzumab govitecan for previously treated, locally advanced or metastatic urothelial carcinoma.

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic Urothelial Cancer 

Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

Genitourinary Cancers | Topics